Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia.
Shimoni
A
A
Leiba
M
M
Schleuning
M
M
Martineau
G
G
Renaud
M
M
Koren-Michowitz
M
M
Ribakovski
E
E
le Coutre
P
P
Arnold
R
R
Guilhot
F
F
Nagler
A
A
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069439:Dasatinib; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage*; D012189:Retrospective Studies; D016019:Survival Analysis; D013844:Thiazoles / Q000008:administration & dosage*; D016896:Treatment Outcome; D055815:Young Adult
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; C498826:nilotinib; D000069439:Dasatinib